1. Scrip
  2. >>Business
  3. >>Earnings

J&J Expects Revenue Growth Despite Stelara Biosimilars, IRA Impact

 
• By Joseph Haas

Innovative medicine grew 4% during Q4 2024 and brought in $57bn during the full year, one year ahead of internal projections. Spravato topped the blockbuster mark in its fifth year on market.

J&J predicts 2025 revenue growth despite the impact of Stelara biosimilars • Source: Shutterstock
Key Takeaways
  • Johnson & Johnson expects roughly 3% sales growth in 2025 despite biosimilar erosion for Stelara and a projected $2bn revenue loss attributed to impact of the Inflation Reduction Act.
  • Innovative medicine grew 4% year-over-year and topped the $57bn sales mark for full-year 2024, one year ahead of schedule.
  • Darzalex, up 21% to $3.08bn during the fourth quarter, led the unit’s growth.

Johnson & Johnson is confident that growth products will get it successfully through the twin headwinds of US and EU biosimilar erosion for Stelara (ustekinumab) and a projected $2bn loss...

The health care giant reported more than $14.3bn in sales during the fourth quarter for its innovative medicine business, growth of 4.4% year-over-year. The full-year total for innovative medicine fell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

More from Strategy

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.